IRONHealthcare · BiotechnologyIRON Stock Forecast: Disc Medicine, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Disc Medicine, Inc. hold a median 12-month price target of $100 — +25.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
IRON stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Disc Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (68): The shares have been drifting up relative to others.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
IRON stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +25.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $118 → $120 |
| 16 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 16 June 2026 | Morgan Stanley | Maintains | Overweight | $80 → $85 |
| 10 June 2026 | Wedbush | Reiterates | Outperform | — |
| 10 June 2026 | Wedbush | Reiterates | Outperform | $88 |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 2 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 17 Feb 2026 | BMO Capital | Maintains | Outperform | — |
| 17 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 17 Feb 2026 | Stifel | Maintains | Buy | — |
| 17 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 17 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 16 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 10 Nov 2025 | Truist Securities | Maintains | Buy | — |
| 3 Nov 2025 | Stifel | Reinstates | Buy | $125 |
| 30 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 17 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 17 Oct 2025 | Raymond James | Maintains | Strong Buy | — |
| 17 Oct 2025 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRON appears on the weeks it earns a place.
IRON analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Disc Medicine, Inc. (IRON) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.0×
- Price / sales
- —
- Price / book
- 4.8×
- EV / EBITDA
- −9.0×
Cheaper than 66% of US stocks
Cheaper than 23% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −39.1%
- Return on assets
- −24.0%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IRON vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Disc Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about IRON stock
What is the IRON stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Disc Medicine, Inc. have a median 12-month price target of $100, with estimates ranging from $79 to $128. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRON stock a buy right now?
Of the 13 analysts covering Disc Medicine, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Disc Medicine, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRON?
As at 22 Aug 2026, Disc Medicine, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (68 of 100).
Will IRON stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +25.3% from the last close, and Ticker Nerd's factor model ranks Disc Medicine, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRON stock forecast for 2030?
No analyst covering Disc Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $128 over the next 12 months.
How has IRON stock performed over the past year?
Disc Medicine, Inc. returned +33.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Disc Medicine, Inc. do?
Disc Medicine Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases.
About Disc Medicine, Inc.
Disc Medicine Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It targets fundamental biological pathways associated with the formation and function of red blood cells, particularly heme biosynthesis and iron homeostasis, to address unmet needs in blood disorders. The company's pipeline features bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria, X-linked protoporphyria, and Diamond-Blackfan Anemia; DISC-0974 for anemia in myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and related hematologic conditions. Preclinical efforts include DISC-0998. Operating in the biotechnology sector, Disc Medicine Inc. advances innovative therapies aimed at rare and chronic blood disorders, positioning it as a key player in hematology research and patient care. Founded in 2017 and headquartered in Watertown, Massachusetts, the company emphasizes turning scientific discoveries into effective medicines.
CEO Dr. John D. Quisel Esq., J.D., Ph.D. · 165 employees · United States · https://www.discmedicine.com